# CISH Inactivated TILs in the Treatment of NSCLC

> **NCT05566223** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Intima Bioscience, Inc.**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Metastatic Non Small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- Squamous Cell Lung Cancer
- Adenocarcinoma of Lung
- Large Cell Lung Cancer

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** CISH Inactivated TIL
- **DRUG:** Aldesleukin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05566223
- **Lead sponsor:** Intima Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02
- **Primary completion:** 2025-11
- **Final completion:** 2027-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No recruitment
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05566223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05566223, "CISH Inactivated TILs in the Treatment of NSCLC". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05566223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*